Anest. intenziv. Med. 2013;24(4):230-236
Anaesthesia for irreversible electroporation (IRE) prostatectomy: Reversal of neuromuscular blockade with sugammadex vs neostigmin. Retrospective studyAnaesthesiology - Original Paper
- 1 Anesteziologicko-resuscitační oddělení, Oblastní nemocnice Mladá Boleslav, a. s.
- 2 Centrum robotické chirurgie a urologie, Nemocnice Na Homolce, Praha
- 3 Urologické oddělení, Oblastní nemocnice Mladá Boleslav, a. s.
- 4 Klinika anesteziologie, resuscitace a intenzivní medicíny, FN a LF UP v Olomouci
Objective:
Assessment of factors influencing the reversal of neuromuscular blockade with sugammadex (S) and neostigmin (N) in IRE prostatectomy requiring deep neuromuscular block until the end of surgery.
Type:
Retrospective study, analysis of anaesthesia charts.
Setting:
Department of Urology, Department of Anaesthe-siology and Intensive Therapy.
Materials and methods:
During a 5-month period (November 2011-March 2012) IRE prostatectomy were performed in 35 men in balanced general anaesthesia with rocuronium. At the end of surgery, S 200 mg (BRIDION) or N (NEOSTIGMIN) were administered for the reversal of deep block (TOF-count 0, PTC ≥ 5) or moderate block (TOF-count ≥ 1) respectively. We analysed the relation of the reversal to the rocuronium admini-stration: the intubation dose, total dose (absolute, per kg of body weight, number of supplementing boluses), duration of anaesthesia and ASA using non-parametric Mann Whitney and Fischer exact tests. Results are presented as mean values.
Results:
Sugammadex 200 mg (2.21 mg/kg) was administered in 22 (63%) patients with deep block (BRIDION group), neostigmin (0.027 mg/kg) in 13 (37%) patients with moderate block (NEOSTIGMIN group). Comparing to NEOSTIGMIN, higher doses of rocuronium - absolute dose (82.5 vs 65 mg, p = 0.001) and dose/kg bw (0.85 vs 0.69 mg/kg, p = 0.018) were given, the number of rocuronium boluses was higher (p = 0.013) and the anaesthesia was longer (100 vs 90 min, p = 0.044) in the BRIDION group. A dose of S 200 mg was sufficient in 20 patients (91 %) for block reversal. In 2 patients with a lower sugammadex dose (< 1.6 mg/kg), a supplement dose of 100 mg was required for complete block recovery after 3.5 min.
Conclusion:
In IRE prostatectomy, rocuronium-sugammadex combination appears to be a cost-effective strategy. A standard dose of 200 mg sugammadex at the end of surgery might be insufficient in obese patients (in doses < 1.6 mg/kg).
Keywords: neuromuscular blockade; akcelerometry; reversal; neostigmin; sugammadex; prostatectomy; irreversible electroporation
Received: April 20, 2013; Accepted: May 5, 2013; Published: August 1, 2013 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Haimowitch, L. Interest grows with least - invasive approaches taken by interventional oncology practitionares. Biomedical Bussiness and Technology, 2008, 31, p. 5-8.
- Biki, B., Mascha, E., Moriarty, D., Fitzpatrick, J., Sessler, D., Buggy D. Anesthetic technique for radical prostatectomy surgery affects cancer reccurence. Anesthesiology, 2008, 109, p. 180-187.
Go to original source...
Go to PubMed...
- Rubinski, B. Irreversible electroporation in Medicine. Technology in Cancer Research and Treatment, 2007, 6, p. 255-259.
Go to original source...
Go to PubMed...
- Nikolski, V., Efimov, P. Electroporation of the heart. Europace, 2005, 7, p. S146-S157.
Go to original source...
Go to PubMed...
- Onik, G., Mikus, P., Rubinsky, B. Irreversible electroporation: implications for prostate ablation. Technology in Cancer Research and Treatment, 2007, 6, p. 295-300.
Go to original source...
Go to PubMed...
- Esser, A., Smith, K., Gowrishankar, T., Weaver, J. Towards solid tumor treatment by irreversible electoporation: Intrinsic redstributionof fileds and currents in tissue. Technology in Cancer Research and Treatment, 2007, 6, p. 261-273.
Go to original source...
Go to PubMed...
- Rubinsky, J., Onik, G., Mikus, P. et al. Optimal parameters for the destruction of prostate cancer using irreversible electroporation. J. Urol., 2008, 180, p. 2668-2674.
Go to original source...
Go to PubMed...
- Ball, C., Thomson, K. R., Kavnoudias, H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth. Analg., 2010, 110, p. 1305-1309.
Go to original source...
Go to PubMed...
- Málek, J., Šturma, J., Janík, V., Kurzová, A. Anesteziologická problematika CT navigované ireverzibilní elektroporatizace(přístroj NanoKnife&trade). Anest. Intenziv. Med., 2013, 2, p. 83-89.
- Kolombo, I. Nová technologie miniinvazivní terapie maligních tumorů - NanoKnife® [cit. 2013-04-24]. Dostupný na:http://www.sab-medical.com/nano-knife.php.
- Brausi, M., Gibert, G., Botiicelli, L., Di Gregio, C. Irreversible electroporation, a novel technique for focal ablation of prostate cancer (PCA): Results of a interim pilot safety study in low risk patients with PCA. Eur. Urolog. Suppl., 2011, 10, p. 300.
Go to original source...
- Eleveld, D. J., Kuizenga, K., Proost, J. K., Wierda, J. M. A temporary decrease in twitch response during reversal or rocuronium-induced muscle relaxation with small dose of sugammadex. Anesth. Analg., 2007, 104, 3, p. 582-584.
Go to original source...
Go to PubMed...
- Fuchs-Buder, T. Less is not always more: sugammadex and the risk of underdosing. Eur. J. Anaesthesiol., 2010, 27, 10, p. 849-854.
Go to original source...
Go to PubMed...